AstraZeneca PLC (AZN) Stock: Revenue, Earnings, Margins & Valuation

AstraZeneca PLC (AZN), UK at a glance: revenue structure, segments, costs, margins and earnings from the latest published annual report (FY 2025), visualised as a Sankey diagram and complemented by price chart, P/E valuation and the original SEC filings. All figures in USD. Free and without signup.

AstraZeneca PLC key figures (FY 2025)

AstraZeneca PLC revenue by segment (FY 2025)

AstraZeneca PLC earnings analysis

In the latest reported fiscal year (FY 2025), AstraZeneca PLC generated revenue of 58.74 USD bn. The largest segment is Oncology with 23.70 USD bn, about 40.3 % of total segment revenue. From gross margin (81.9 %) through operating margin (23.4 %) to net margin (17.4 %), the Sankey diagram shows how much of each revenue dollar remains at each stage of the income statement.

AstraZeneca PLC business model

The income statement of AstraZeneca PLC is visualised as a Sankey diagram: from revenue through cost of revenue and operating expenses to net income. The page also shows the price chart, the price-earnings ratio of the last five fiscal years, return on equity and the company's annual and quarterly filings.

More stock analyses like AstraZeneca PLC

• HSBC Holdings plc stock (HSBC)
• Shell plc stock (SHEL)
• ASML Holding NV stock (ASML)
• AT&T Inc. stock (T)
• AppLovin Corp. stock (APP)
• Banco Santander, S.A. stock (SAN.MC)
• Applied Materials Inc. stock (AMAT)
• Bank of America Corp. stock (BAC)
• Apple Inc. stock (AAPL)
• Berkshire Hathaway Inc. stock (BRK-B)

AstraZeneca PLC in detail

• AstraZeneca PLC valuation: P/E, price and risk
• AstraZeneca PLC earnings: quarterly revenue and EPS